Technical Analysis for TERN - Terns Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 8.34 14.25% 1.04
TERN closed up 14.25 percent on Thursday, July 11, 2024, on 2.87 times normal volume. The bulls were able to push the stock to a new 52-week high.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
New 52 Week Closing High Bullish 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 14.25%
Spinning Top Other 14.25%
NR7 Range Contraction 11.95%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 20 hours ago
New 52 Week High about 21 hours ago
2x Volume Pace about 21 hours ago
1.5x Volume Pace about 21 hours ago
3x Volume Pace about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Terns Pharmaceuticals, Inc. Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Glucagon Bile Acid Chronic Liver Diseases Anti Diabetic Drugs

Is TERN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.16
52 Week Low 3.26
Average Volume 1,189,072
200-Day Moving Average 5.98
50-Day Moving Average 6.60
20-Day Moving Average 7.32
10-Day Moving Average 7.18
Average True Range 0.63
RSI (14) 64.66
ADX 17.28
+DI 37.66
-DI 15.81
Chandelier Exit (Long, 3 ATRs) 7.26
Chandelier Exit (Short, 3 ATRs) 8.28
Upper Bollinger Bands 8.28
Lower Bollinger Band 6.35
Percent B (%b) 1.03
BandWidth 26.44
MACD Line 0.24
MACD Signal Line 0.19
MACD Histogram 0.0475
Fundamentals Value
Market Cap 515.37 Million
Num Shares 61.8 Million
EPS -1.15
Price-to-Earnings (P/E) Ratio -7.25
Price-to-Sales 302.64
Price-to-Book 1.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.61
Resistance 3 (R3) 10.63 9.89 10.23
Resistance 2 (R2) 9.89 9.32 9.88 10.10
Resistance 1 (R1) 9.12 8.96 9.51 9.10 9.98
Pivot Point 8.38 8.38 8.58 8.37 8.38
Support 1 (S1) 7.61 7.81 8.00 7.59 6.70
Support 2 (S2) 6.87 7.45 6.86 6.58
Support 3 (S3) 6.10 6.87 6.45
Support 4 (S4) 6.08